Business Wire · Jul 2026
Deep Genomics named Thong Q. Le chair of its board, with Chip Baird moving to chair the audit committee; the company said Le will help guide its next phase of growth and clinical pipeline progress.
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Deep Genomics is a private AI-driven genetic medicines / TechBio company that uses its Biological Foundation Model (BioFM) platform to decode RNA biology, identify disease targets, and design oligonucleotide therapeutics. Public profiles point to Toronto as headquarters, with a Cambridge, MA office/lab; the company is active, partnership-oriented, and centered on lab-in-the-loop AI + biology workflows. Public materials show an initial founding period in 2014 (some later press materials say 2015), Series C financing closed in 2021, and no publicly confirmed material layoffs, acquisitions, or shutdowns surfaced in the researched sources.
Primary product
Biological Foundation Model (BioFM) Platform
Founded
2014
Headquarters
480 University Avenue, Suite 1300, Toronto, Ontario, Canada, M5G 1V2
Team size
80-90
Work style
Hybrid
Industry
Biotechnology Research
Sub-industry
AI-driven genetic medicines / RNA therapeutics
Offices
480 University Avenue, Suite 1300, Toronto, Ontario, Canada, M5G 1V2
1 Canal Park, Suite 300, Cambridge, MA 02141, USA
Business model
Funding
People & investors
Leadership
Chief Executive Officer
Founder, Chief Innovation Officer and Board Member
Chief Operating Officer
Work & culture
Cross-disciplinary and collaborative, with a strong lab-in-the-loop mindset that blends AI, software engineering, computational biology, and wet-lab science. Public hiring materials emphasize fast-paced experimentation, reproducibility, learning, and close teamwork across Toronto and Cambridge.
Work style
Hybrid
Compensation
Public job postings advertise competitive compensation with meaningful stock ownership; one Canada-based role listed a CAD $175,000-$200,000 base salary range, while U.S.-based pay may differ.
Benefits
Competitive compensation
Meaningful stock ownership
Health coverage
Vision coverage
Dental coverage
Product & market
Differentiators
- —Biological Foundation Model (BioFM) platform
- —Lab-in-the-loop experimental design and validation
- —Flagship RNA models including BigRNA and REPRESS
- —Deep learning applied directly to RNA biology and therapeutic design
- —Integrated AI, software, and wet-lab stack
- —Focus on steric-blocking oligonucleotides and RNA therapeutics
Technology
Python
PyTorch
Google Cloud Platform
Terraform
Scale & contact
Estimated revenue
US$1M-$10M
Estimated monthly visits
9.2K
Traffic estimate as of Jul 2026
Latest news
Deep Genomics · Oct 2025
Deep Genomics added Thong Q. Le and Paul Sekhri to the board, emphasizing strategic life-sciences and deal-making experience as the company advances AI-powered genetic medicines.
Deep Genomics · Jun 2025
The company appointed Vic Myer as chair and Richard Scheller to its Scientific Advisory Board to support AI-driven genomic R&D and drug discovery.
Deep Genomics · May 2025
Deep Genomics announced REPRESS, a new model predicting miRNA binding and mRNA degradation from sequence, and released it for non-commercial use via GitHub.
Open Positions
2 jobs at Deep Genomics
Senior Research Scientist, Machine Learning (BioFM)
HybridToronto, Ontario1mo ago
Hybrid
Full-time